MTOR and cancer: Our study and others hold particular significance, especially when considering the weak monotherapeutic activity of mTOR inhibitors (everolimus and sirolimus), which has already been demonstrated in HCC [36,37,38], alongside the efficacy of the vinorelbine in other cancer types [27,28,29,30,46,52].